Glycomine
Biotechnology company developing substrate replacement therapies for congenital disorders of glycosylation (CDG), rare genetic diseases affecting sugar metabolism.
Notes
Glycomine is a biotechnology company developing treatments for congenital disorders of glycosylation (CDG), a group of rare genetic diseases that affect the body's ability to properly attach sugar molecules (glycans) to proteins. These disorders can cause a wide range of symptoms including neurological problems, organ dysfunction, and developmental delays.
The company's approach involves substrate replacement therapy, providing the missing or deficient sugars directly to patients. Lead program GLM101 is being developed for PMM2-CDG (also known as CDG-Ia), the most common form of CDG.
Glycomine was founded based on research from Hudson Freeze's laboratory at Sanford Burnham Prebys Medical Discovery Institute and is backed by Abingworth, a leading life sciences investment firm.
Team
- Peter McWilliams - CEO
- LinkedIn: linkedin.com/in/petermcwilliams
- Hudson Freeze, Ph.D. - Scientific Co-founder (Sanford Burnham Prebys)
- Experienced team in rare disease drug development
Additional Research Findings
- Founded in 2012, based in San Carlos, California
- Portfolio company of Abingworth
- Focus on congenital disorders of glycosylation (CDG)
- Lead program GLM101 for PMM2-CDG
- Substrate replacement therapy approach
- Based on research from Sanford Burnham Prebys
- Orphan drug designation for lead program
- CDG affects approximately 2,000+ patients worldwide
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Abingworth | London, UK / Boston, USA | biotech-focused | seedseries-a+3 | 34 |